Use of Proton-Pump Inhibitors and Risk of COVID-19 Infection

For UCSF Faculty and Staff: Please login via MyAccess to request access to update your Project.

May 24, 2020 - December 31, 2020

Project contact: Vivek Rudrapatna

PI: Vivek Rudrapatna, MD, PhD

Public Summary

Gastroesophageal reflux disease and the use of proton pump inhibitor medications are both widely prevalent in the population; they have both been mechanistically tied to the development of pneumonia in general but are not well understood as far as COVID-19 is concerned. More importantly, both GERD and PPI use may represent *reversible risk factors* for the development of COVID-19. We propose to use electronic health records data to establish an association between these two putative risk factors and the infection itself, in the hopes of identifying a modifiable risk factor that can reduce COVID19 susceptibility.

Type of Research: Clinical / Translational Science study (excluding trials)

Topics: Clinical Presentation of Infection, Co-Morbidities, Gastroesophageal Reflux Disease (GERD), Computational Analysis, Epidemiology, Clinical History, Clinical Outcome, Risk Factors